Anticoagulation for Paroxysmal/Non-Persistent Atrial Fibrillation with High CHA₂DS₂-VASc Score

Introduction to Anticoagulation Guidelines

The American College of Cardiology recommends initiating anticoagulation for patients with paroxysmal or non-persistent atrial fibrillation when the CHA₂DS₂-VASc score is high (≥2 in men or ≥3 in women), as stroke risk is identical regardless of AF pattern—paroxysmal, persistent, or permanent AF all carry the same thromboembolic risk 1, 2
The selection of anticoagulant therapy should be based on the risk of thromboembolism, irrespective of whether the AF pattern is paroxysmal, persistent, or permanent, with a Class 1, Level of Evidence: B recommendation 1

For men with CHA₂DS₂-VASc ≥2 or women with ≥3, oral anticoagulation is definitively recommended (Class 1, Level of Evidence: A) 2, 3
Direct oral anticoagulants (DOACs) are preferred over warfarin as first-line therapy (Class 1, Level of Evidence: A) 1, 2, 3
DOAC options include apixaban, dabigatran, rivaroxaban, or edoxaban 2, 3

DOACs are recommended over warfarin in DOAC-eligible patients with AF (except with moderate or severe mitral stenosis or a mechanical heart valve) 1, 2
When DOAC trials are considered as a group, they were at least noninferior and, in some trials, superior to warfarin for preventing stroke and systemic embolism, with lower risks of serious bleeding 1

The HAS-BLED score should be calculated to identify modifiable bleeding risk factors (hypertension, abnormal renal/liver function, stroke, bleeding history, labile INR, elderly, drugs/alcohol) 4, 5
A HAS-BLED score ≥3 requires more frequent monitoring and correction of modifiable risk factors, but is NOT a contraindication to anticoagulation 4, 5

Anticoagulant therapy should be individualized based on shared decision-making after discussion of the absolute and relative risks of stroke and bleeding, as well as the patient's values and preferences (Class 1, Level of Evidence: C) 1
Selection should take into account risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics 1, 2